9 citations
,
February 2019 in “BMC cancer” This study found that M30 may protect against cyclophosphamide-induced alopecia in mice by enhancing hair growth and preventing abnormal hair, suggesting its potential as a treatment.
3 citations
,
October 2024 in “Advances in Therapy” In this study, Chinese children with central precocious puberty receiving 6-monthly injections of triptorelin showed luteinizing hormone suppression and slowed development of sexual characteristics over 12 months, without severe adverse events, suggesting it may be an effective treatment option for this population.
1 citations
,
March 2011 in “Informa Healthcare eBooks” Hormonal therapy is effective for treating acne in adult women, especially with signs of high androgen levels.
This review examines complex regional pain syndrome (CRPS I) mechanisms, including immune dysregulation and psychological factors, but reports no new clinical results; the authors highlight potential diagnostic refinements.
July 2026 in “Frontiers in Immunology” This review summarizes recent findings on the role of lactylation, a novel post-translational modification, in skin diseases, suggesting its potential as a therapeutic target by linking metabolism, epigenetic regulation, and inflammatory processes.
The researchers presented a rare case of a four-year-old developing scarring alopecia after a two-week ICU stay, highlighting the challenge of diagnosing pressure alopecia in children and the crucial role of early detection and trichoscopy in preventing permanent hair loss.
This narrative review highlights the potential of exosomes in regenerative and aesthetic dermatology, particularly in India, but emphasizes that their clinical use is still investigational due to limited and diverse study data, insufficient long-term safety information, and regulatory challenges.
This study found that human placental extract significantly improved melasma, chronic ulcers, and alopecia areata without major adverse effects, suggesting its effectiveness and safety for these conditions.
January 2024 in “Dermatology Review” This study assessed the quality of social media information about thread lifting and found it generally low across platforms, with YouTube rated highest. The researchers emphasized the need for dermatologists and plastic surgeons to provide better-quality content and for platforms to monitor health-related information conscientiously.
January 2014 in “Side effects of drugs annual” This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.
January 2005 in “Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München)” This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.
This study introduces PROMETHEUS, a framework that organizes causal claims from scientific texts into navigable and persistent "causal atlases," enhancing research by highlighting localized evidence, agreement, and contradictions within complex data sets.
September 2016 in “Más dermatología” New factors in female hair loss include genetics, hormones, stress, and inflammation; future treatments should also focus on these areas and consider the patient's emotional well-being.
3 citations
,
June 2025 in “Journal of Cosmetic Dermatology” Using combined fat and growth factors can effectively treat hair loss after facial fillers.
June 2024 in “Archives of dermatological research” In this self-controlled comparative study of 16 women with Female Pattern Hair Loss, MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced cases compared to standard Minoxidil treatment, though overall effectiveness was similar.
February 2026 in “Archives of Dermatological Research” In this study, microneedle-assisted delivery of polyglutamate significantly improved hair parameters, scalp symptoms, and quality of life in androgenetic alopecia patients, with no serious adverse reactions reported.
May 2026 in “Dove Medical Press (Taylor and Francis Group)” This study found that both buffy coat and apheresis PRP are effective for treating androgenetic alopecia, with buffy coat PRP associated with higher patient-reported improvement despite lower platelet counts.
May 2026 in “Clinical Cosmetic and Investigational Dermatology” This study found that while both buffy coat and apheresis PRP improved androgenetic alopecia, the buffy coat method was linked to greater patient-reported improvement despite having lower platelet counts.
January 2026 in “Dermatologic Therapy” This study found that in patients with female androgenetic alopecia, mesodermal injection of 0.5% minoxidil was more effective in increasing hair density and improving hairline height than topical 2% minoxidil, with comparable safety over 16 weeks.
August 2026 in “Dermatology and Therapy” This review discusses current and emerging treatments for discoid lupus erythematosus, suggesting that new biologic and small-molecule therapies may improve disease control when combined with traditional management.
July 2024 in “Journal of Cosmetic Dermatology” This case study suggests that rose stem cell-derived exosomes, administered via noninvasive electroporation, may promote hair regeneration in androgenetic alopecia; larger studies are needed to confirm these findings.
April 2024 in “International Journal of Dermatology” This study reviewed cases of filler-induced alopecia and found that hyaluronic acid injections were most commonly associated with this condition, highlighting that hyaluronidase treatments can rapidly restore hair density, while alternative interventions need further exploration.
46 citations
,
July 2007 in “Journal of the American Academy of Dermatology” This letter discusses the psychological impact of alopecia areata, highlighting its association with increased depression and anxiety, but reports no new clinical findings.
1 citations
,
November 2024 in “Applied Sciences” This study reviewed existing evidence on using PRP to manage ankle osteoarthritis, reporting significant short-term improvements in pain and function in patients with stage II-III OA, but concluded there is insufficient high-quality evidence to establish its overall effectiveness and safety.
4 citations
,
November 2024 in “International Journal of Dermatology” This study examines the link between testosterone use and hair health in males, stressing the importance of developing guidelines for safe usage due to associated health risks like liver toxicity, gynecomastia, and hair loss.
January 2026 in “Dermatologic Therapy” This review indicates that while microneedling shows potential for managing androgenetic alopecia, particularly in combination with other treatments, the existing evidence is of low to moderate quality, and more robust trials are needed to confirm its clinical efficacy and safety.
May 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” This randomized controlled trial found that intralesional vitamin D3 was as effective and safe as intralesional triamcinolone acetonide for treating patchy alopecia areata on the scalp, with no significant influence from serum vitamin D levels on treatment response.
28 citations
,
January 2023 in “Cell Transplantation” This study found that the Hy-Tissue Nanofat product isolates a significant number of proliferative nucleated cells and shows potential for regenerative medicine due to its rich content of adipose-derived stem cells and pluripotent MUSE cells.
January 2026 in “PubMed Central” This article reviews self-assembled nanoparticles, highlighting their promising role in drug delivery systems but noting the need for further research on stability and large-scale industrial application; it reports no new clinical findings.
1 citations
,
August 2023 in “Advanced Drug Delivery Reviews” This review discusses various microneedle technologies for long-acting drug delivery, highlighting design considerations and challenges in bringing these minimally invasive devices to market, but it reports no new clinical results.